These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6516702)

  • 1. [Analysis of F.IX-inhibitor bypassing activity contained in a commercial prothrombin complex concentrate (Proplex)].
    Sugimoto M; Fujimura Y; Okubo Y; Takahashi Y; Yoshioka A; Fukui H
    Nihon Ketsueki Gakkai Zasshi; 1984 Aug; 47(5):1181-9. PubMed ID: 6516702
    [No Abstract]   [Full Text] [Related]  

  • 2. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of hemophilia B with a new clotting-factor concentrate.
    Hoag MS; Johnson FF; Robinson JA; Aggeler PM
    N Engl J Med; 1969 Mar; 280(11):581-6. PubMed ID: 5764825
    [No Abstract]   [Full Text] [Related]  

  • 4. Surgical operation in hemophilia B. Use of factor IX concentrate.
    Kasper CK
    Calif Med; 1970 Jul; 113(1):4-8. PubMed ID: 5520728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor.
    Mizon P; Goudemand J; Jude B; Marey A
    Ann Hematol; 1992 Jun; 64(6):309-11. PubMed ID: 1637888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC; Matts L; Eisele J; Czachur M; Saidi P
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 8. [Coagulation factor IX inhibitor in hemophilia B].
    Lutze G; Mittler U; Presser HJ; Urbahn H
    Z Med Lab Diagn; 1990; 31(2):113-9. PubMed ID: 2343619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery in haemophilic patients with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of proplex in a hemophilia B patient].
    Onda T; Umezawa F; Tahara H; Yoshino N; Hoshi Y; Akatsuka J
    Rinsho Ketsueki; 1984 Aug; 25(8):1299-305. PubMed ID: 6513043
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
    Buchanan GR; Kevy SV
    Pediatrics; 1978 Nov; 62(5):767-74. PubMed ID: 724319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preparation of the factors IX, II, and X concentrate by means of DEAE cellulos and its therapeutic effectiveness.
    Uszyński L; Poszwiński P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(5):591-4. PubMed ID: 54310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
    Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experiences with chromatographic DEAE adsorbed prothrombin complex for control of bleeding and multiple tooth extraction in hemophilia B patients.
    Onishi H; Izuchi K; Matsumoto T; Kato R; Kusunose K
    Nihon Ketsueki Gakkai Zasshi; 1971 Aug; 34(4):513-6. PubMed ID: 5317288
    [No Abstract]   [Full Text] [Related]  

  • 15. Prothrombin complex concentrates: preparation, properties, and clinical uses.
    White GC; Lundblad RL; Kingdon HS
    Curr Top Hematol; 1979; 2():203-44. PubMed ID: 318075
    [No Abstract]   [Full Text] [Related]  

  • 16. [The P.P.S.B. coagulant fraction].
    Soulier JP; Steinbuch M
    Nouv Presse Med; 1975 Oct; 4(36):2581-4. PubMed ID: 812061
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
    Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anasarca improved by extracorporeal ultrafiltration through an internal shunt in a case of severe haemophilia B with inhibitor and steroid-resistant nephrotic syndrome.
    Satomura A; Takahashi S; Fujita T; Matsumoto K; Shichino H; Mugishima H
    Haemophilia; 2006 Jan; 12(1):103-5. PubMed ID: 16409185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.